Category: Liver Cancer
Clinical outcome of immunotherapy with dendritic cell vaccine and cytokine‐induced killer cell therapy in hepatobiliary and pancreatic cancer
Clinical outcome of immunotherapy with dendritic cell vaccine and cytokine‐induced killer cell therapy in hepatobiliary and pancreatic cancer Contact Us Summary The goal of this study was to discover the therapeutic effects of adoptive immunotherapy following dendritic cell (DC) vaccine and cytokine-induced killer (CIK) cell therapy and evaluate its cytotoxicity, survival benefits and quality of […]
Adoptive Immunotherapy for Pancreatic Cancer Using MUC1 Peptide-pulsed Dendritic Cells and Activated T Lymphocytes
Adoptive Immunotherapy for Pancreatic Cancer Using MUC1 Peptide-pulsed Dendritic Cells and Activated T Lymphocytes Contact Us Summary This trial investigated the efficacy and safety of this DC-based adjuvant immunotherapy with patients with Hepatocellular cancer. The results show that adjuvant immunotherapy with DC vaccine reduces the risk of tumour recurrence in HCC patients who underwent standard […]
A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma Contact Us Summary This study evaluated the safety and efficacy of adjuvant dendritic cell (DC) therapy in HCC patients who received primary treatment for hepatocellular carcinoma (HCC). Adjuvant DC vaccine for HCC was safe and well tolerated in […]
Phase I/II study of Immunotherapy using Tumor Antigen-pulsed Dendritic Cells in patients with Hepatocellular Carcinoma (HCC)
Phase I/II study of Immunotherapy using Tumor Antigen-pulsed Dendritic Cells in patients with Hepatocellular Carcinoma (HCC) Contact Us Summary This study evaluated the safety, feasibility and efficacy of multiple tumor-associated antigen (TAA)-pulsed DC vaccine in patients with hepatocellular carcinoma. The feasibility, safety and immune activity were confirmed in the patients. Patients characteristics 5 Patients with […]
Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma
Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma Contact Us Summary This study investigated the clinical utilization of an autologous tumor lysate-pulsed dendritic cell vaccine plus ex vivo activated T cell transfer (ATVAC) in an adjuvant setting for postoperative Hepatocellular carcinoma. The findings suggest A postoperative […]
Effect of NK cell immunotherapy on immune function in patients with hepatic carcinoma: A preliminary clinical study
Effect of NK cell immunotherapy on immune function in patients with hepatic carcinoma: A preliminary clinical study Contact Us Summary This study investigates the effectiveness of adoptive transfer of KIR ligand-mismatched highly activated nature killer (HANK) cells in patients with hepatic carcinoma. This is the first study on the benefits of HANK cell immunotherapy for […]
Clinical efficacy of DC-CIK combined with sorafenib in the treatment of advanced hepatocellular carcinoma
Clinical efficacy of DC-CIK combined with sorafenib in the treatment of advanced hepatocellular carcinoma Contact Us Summary The aim of this study is to explore the efficacy and safety of the combination treatment of dendritic cells and cytokine-induced killers (DC-CIK) and sorafenib in patients with advanced hepatocellular carcinoma (HCC).DC-CIK combined with sorafenib could improve the […]
Efficacy of cytokine-induced killer cell-based immunotherapy for hepatocellular carcinoma
Efficacy of cytokine-induced killer cell-based immunotherapy for hepatocellular carcinoma DC vaccines in detail Contact Us Summary The study aims to investigate the efficacy of autologous transplantations of cytokine-induced killer (CIK) cells as an adjuvant therapy for patients with hepatocellular carcinoma HCC. The findings suggest that the therapy was linked with better survival for patients with […]
A randomized controlled trial on patients with or without adjuvant autologous cytokine- induced killer cells after curative resection for hepatocellular carcinoma
A randomized controlled trial on patients with or without adjuvant autologous cytokine- induced killer cells after curative resection for hepatocellular carcinoma Contact Us Summary The study aims to investigate the safety and efficacy of Autologous cytokine-induced killer (CIK) cells therapy on patients with hepatocellular carcinoma (HCC). The findings suggest that the therapy was safe and […]
Allogenic Natural Killer Cell Immunotherapy Combined with Irreversible Electroporation for Stage IV Hepatocellular Carcinoma: Survival Outcome
Allogenic Natural Killer Cell Immunotherapy Combined with Irreversible Electroporation for Stage IV Hepatocellular Carcinoma: Survival Outcome Contact Us Summary The study evaluates the clinical effectiveness of irreversible electroporation (IRE) in combination with immunotherapy using allogenic natural killer cells (NK) for patients with stage IV hepatocellular carcinoma (HCC). The effect of the IRE-NK enhanced immune function, […]
